GeneFerm Biotechnology (1796) Stock Overview
Develops, manufactures, and sells fermented health products in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
1796 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
GeneFerm Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$29.50 |
| 52 Week High | NT$61.40 |
| 52 Week Low | NT$28.25 |
| Beta | 0.068 |
| 1 Month Change | -3.91% |
| 3 Month Change | -13.11% |
| 1 Year Change | -50.75% |
| 3 Year Change | -67.40% |
| 5 Year Change | -13.24% |
| Change since IPO | -67.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1796 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | -1.8% | -2.3% | -3.1% |
| 1Y | -50.8% | -25.0% | 78.6% |
Return vs Industry: 1796 underperformed the TW Personal Products industry which returned -25.1% over the past year.
Return vs Market: 1796 underperformed the TW Market which returned 79% over the past year.
Price Volatility
| 1796 volatility | |
|---|---|
| 1796 Average Weekly Movement | 6.9% |
| Personal Products Industry Average Movement | 3.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in TW Market | 11.2% |
| 10% least volatile stocks in TW Market | 2.4% |
Stable Share Price: 1796 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1796's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Jinde Jin | www.geneferm.com |
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, and fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; and microbial fermentation toll manufacturing services.
GeneFerm Biotechnology Co., Ltd. Fundamentals Summary
| 1796 fundamental statistics | |
|---|---|
| Market cap | NT$1.22b |
| Earnings (TTM) | NT$17.07m |
| Revenue (TTM) | NT$664.94m |
Is 1796 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1796 income statement (TTM) | |
|---|---|
| Revenue | NT$664.94m |
| Cost of Revenue | NT$494.00m |
| Gross Profit | NT$170.94m |
| Other Expenses | NT$153.86m |
| Earnings | NT$17.07m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 25.71% |
| Net Profit Margin | 2.57% |
| Debt/Equity Ratio | 28.3% |
How did 1796 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 07:19 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeneFerm Biotechnology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.